Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Hepatitis01:25

Hepatitis

Hepatitis is an inflammatory condition of the liver most commonly caused by hepatotropic viruses (A–E), though non-infectious causes such as alcohol and drugs also exist.Hepatitis AHepatitis A virus (HAV) is a non-enveloped RNA virus of the Picornaviridae family. It is primarily transmitted via the fecal-oral route, typically through ingestion of contaminated food or water. After ingestion, HAV enters the bloodstream through the oropharynx or intestinal epithelium and reaches the liver. The...
Viral Hepatitis I: Introduction01:28

Viral Hepatitis I: Introduction

Viral hepatitis is an inflammatory condition of the liver caused by infection with hepatotropic viruses, most commonly hepatitis A, B, C, D, and E. Despite variations in structure and transmission, all viruses mentioned infect hepatocytes and provoke immune responses that can hinder liver function. Additionally, some non-hepatotropic viruses can also lead to hepatic inflammation.Hepatitis A VirusHepatitis A virus (HAV) is transmitted through the fecal–oral route, typically by ingestion of food...
Viral Recombination00:57

Viral Recombination

Cells are sometimes infected by more than one virus at once. When two viruses disassemble to expose their genomes for replication in the same cell, similar regions of their genomes can pair together and exchange sequences in a process called recombination. Alternatively, viruses with segmented genomes can swap segments in a process called reassortment.
Antigens Involved in Adaptive Immunity01:26

Antigens Involved in Adaptive Immunity

An antigen is any substance the immune system identifies as foreign and potentially harmful to the body, prompting an immune response. Antigens have two functional properties: immunogenicity and reactivity. Immunogenicity is the ability of an antigen to stimulate a specific immune response. At the same time, reactivity describes the antigen's ability to react with the cells and antibodies produced in response to it.
Complete Antigens
Complete antigens possess both immunogenicity and reactivity.

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Gene overexpression reduces inhibitory metabolites to enhance CHO cell growth and IgG1 production.

NPJ systems biology and applications·2026
Same author

<i>Special Issue:</i> 13th International Conference on Computational Advances in Bio and Medical Sciences.

Journal of computational biology : a journal of computational molecular cell biology·2026
Same author

A high prevalence of hepatitis B virus strains sharing a single S gene variant in Pakistan.

Infection, genetics and evolution : journal of molecular epidemiology and evolutionary genetics in infectious diseases·2026
Same author

Assessment of PHRED Score Characteristics in Illumina MiSeq Amplicon Sequencing.

Journal of computational biology : a journal of computational molecular cell biology·2026
Same author

Development and validation of a cell-based methodology to evaluate filgrastim relative affinity to granulocyte colony-stimulating factor receptor.

Journal of immunoassay & immunochemistry·2025
Same author

<i>Special Section:</i> 12th International Computational Advances in Bio and Medical Sciences (ICCABS 2023).

Journal of computational biology : a journal of computational molecular cell biology·2025

Related Experiment Video

Updated: May 24, 2026

Modeling Hepatitis B Virus Infection in Non-Hepatic 293T-NE-3NRs Cells
09:02

Modeling Hepatitis B Virus Infection in Non-Hepatic 293T-NE-3NRs Cells

Published on: June 5, 2020

Hepatitis C virus antigenic convergence.

David S Campo1, Zoya Dimitrova, Jonny Yokosawa

  • 1Molecular Epidemiology & Bioinformatics Laboratory, Division of Viral Hepatitis, Centers for Disease Control and Prevention, Atlanta, USA.

Scientific Reports
|February 23, 2012
PubMed
Summary
This summary is machine-generated.

Developing a hepatitis C virus (HCV) vaccine is challenging due to limited understanding of epitope cross-immunoreactivity. This study reveals that HCV hypervariable region 1 (HVR1) antigenic diversity is limited and predictable, offering vaccine development insights.

More Related Videos

A Protocol for Analyzing Hepatitis C Virus Replication
13:04

A Protocol for Analyzing Hepatitis C Virus Replication

Published on: June 26, 2014

Two Methods of Heterokaryon Formation to Discover HCV Restriction Factors
16:49

Two Methods of Heterokaryon Formation to Discover HCV Restriction Factors

Published on: July 16, 2012

Related Experiment Videos

Last Updated: May 24, 2026

Modeling Hepatitis B Virus Infection in Non-Hepatic 293T-NE-3NRs Cells
09:02

Modeling Hepatitis B Virus Infection in Non-Hepatic 293T-NE-3NRs Cells

Published on: June 5, 2020

A Protocol for Analyzing Hepatitis C Virus Replication
13:04

A Protocol for Analyzing Hepatitis C Virus Replication

Published on: June 26, 2014

Two Methods of Heterokaryon Formation to Discover HCV Restriction Factors
16:49

Two Methods of Heterokaryon Formation to Discover HCV Restriction Factors

Published on: July 16, 2012

Area of Science:

  • Virology
  • Immunology
  • Vaccine Development

Background:

  • Hepatitis C virus (HCV) vaccine development faces challenges due to poorly understood cross-immunoreactivity among diverse epitopes.
  • The hypervariable region 1 (HVR1) of HCV is a key target for immune responses but exhibits significant sequence heterogeneity.

Purpose of the Study:

  • To quantitatively analyze cross-immunoreactivity among HCV HVR1 variants.
  • To develop a predictive model for HVR1 cross-immunoreactivity based on amino acid sequences.
  • To assess the implications of HVR1 antigenic diversity for HCV vaccine design.

Main Methods:

  • Utilized synthetic peptides representing HCV HVR1 variants for mouse immunization.
  • Performed quantitative analysis of 26,883 immunological reactions between peptide pairs.
  • Mapped peptide variants within the HVR1 sequence space and visualized it as a network.
  • Correlated network centrality with observed cross-immunoreactivity.

Main Results:

  • The distribution of cross-immunoreactivity among HVR1 variants was skewed, with a few variants eliciting broad antibody responses.
  • HCV HVR1 cross-immunoreactivity could be accurately modeled using amino acid sequence data alone.
  • HVR1 variants with higher network centrality exhibited broader cross-reactivity.
  • The sequence space analysis indicated convergent and limited antigenic diversity across HCV genotypes and subtypes.

Conclusions:

  • HCV HVR1 antigenic diversity is extensively convergent and effectively limited.
  • Predictive modeling of cross-immunoreactivity based on sequence is feasible.
  • Findings provide significant insights for the rational design of HCV vaccines targeting HVR1.